These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 36158149)
1. New aspects in cardiorenal syndrome and HFpEF. Méndez AB; Azancot MA; Olivella A; Soler MJ Clin Kidney J; 2022 Oct; 15(10):1807-1815. PubMed ID: 36158149 [TBL] [Abstract][Full Text] [Related]
2. Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity. Agrawal A; Naranjo M; Kanjanahattakij N; Rangaswami J; Gupta S Heart Fail Rev; 2019 Jul; 24(4):421-437. PubMed ID: 31127482 [TBL] [Abstract][Full Text] [Related]
3. Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. Elkammash A; Tam SSC; Yogarajah G; You J Cureus; 2023 Feb; 15(2):e35030. PubMed ID: 36938226 [TBL] [Abstract][Full Text] [Related]
4. Cardiorenal syndrome and diabetes: an evil pairing. Méndez Fernández AB; Vergara Arana A; Olivella San Emeterio A; Azancot Rivero MA; Soriano Colome T; Soler Romeo MJ Front Cardiovasc Med; 2023; 10():1185707. PubMed ID: 37234376 [TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Mentz RJ; Brunton SA; Rangaswami J Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185 [TBL] [Abstract][Full Text] [Related]
6. Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens-From a Cardiologist's View. Mitsas AC; Elzawawi M; Mavrogeni S; Boekels M; Khan A; Eldawy M; Stamatakis I; Kouris D; Daboul B; Gunkel O; Bigalke B; van Gisteren L; Almaghrabi S; Noutsias M J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498617 [TBL] [Abstract][Full Text] [Related]
7. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Rao S Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413 [TBL] [Abstract][Full Text] [Related]
8. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials. Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223 [TBL] [Abstract][Full Text] [Related]
9. Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease. Bonacchi G; Rossi VA; Garofalo M; Mollace R; Uccello G; Pieragnoli P; Checchi L; Perrotta L; Voltolini L; Ricciardi G; Beltrami M Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790943 [TBL] [Abstract][Full Text] [Related]
10. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction. Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551 [TBL] [Abstract][Full Text] [Related]
11. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis. Pozzi A; Cirelli C; Merlo A; Rea F; Scangiuzzi C; Tavano E; Iorio A; Kristensen SL; Wong C; Iacovoni A; Corrado G Heart Fail Rev; 2024 Jan; 29(1):207-217. PubMed ID: 37917192 [TBL] [Abstract][Full Text] [Related]
12. Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. Bayes-Genis A; Bisbal F; Núñez J; Santas E; Lupón J; Rossignol P; Paulus W J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32294958 [TBL] [Abstract][Full Text] [Related]
14. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. Xiang B; Zhang R; Wu X; Zhou X JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813 [TBL] [Abstract][Full Text] [Related]
15. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633 [TBL] [Abstract][Full Text] [Related]
17. A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction. Epperson J; Athar ZM; Arshad M; Chen E Cureus; 2024 Apr; 16(4):e57380. PubMed ID: 38694659 [TBL] [Abstract][Full Text] [Related]
18. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Gevaert AB; Kataria R; Zannad F; Sauer AJ; Damman K; Sharma K; Shah SJ; Van Spall HGC Heart; 2022 Aug; 108(17):1342-1350. PubMed ID: 35022210 [TBL] [Abstract][Full Text] [Related]
19. Variation in intraabdominal pressure in patients with acute heart failure according to left ventricular ejection fraction. Results of an intraabdominal pressure study. Rubio Gracia J; Giménez López I; Josa Laorden C; Sánchez Marteles M; Garcés Horna V; de la Rica Escuín ML; Pérez Calvo JI Rev Clin Esp (Barc); 2021; 221(7):384-392. PubMed ID: 34103276 [TBL] [Abstract][Full Text] [Related]